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INTRODUCTION
Acyclovir (9-(2-hydroxyethoxymethyl)guanine, acycloguanosine) and cisplatin (cisdiaminedichloroplatinum(II), cis-DDP) are two drugs currently used in antiviral and anticancer therapy, respectively.
Acyclovir is a nucleoside analogue with potent activity towards herpes virus infections. Acyclovirtriphosphate is preferentially formed in infected cells and inhibits viral DNA synthesis either selectively interfering with viral DNA polymerase or leading to premature chain termination (1).
The metal-coordinating properties of acyclovir are of current interest (2-5) from a mechanistic point of view, some DNA polymerases containing (Zn2+) and/or being 2+ Mn2+ r 2+ activated by metal ions (Mg o Co ). Moreover, metal complexes of acyclovir may exhibit antiviral activity different from that ofthe free ligand (6).
Cisplatin is one of the most successful antitumour drugs developed in recent years and numerous studies have revealed that its cytotoxic activity depends upon the interaction with cellular DNA. Cisplatin and related platinum(II) analogues coordinate two neighbouring purines, thus producing bifunctional lesions able to inhibit DNA replication and/or transcription (7) . Platinum(II) complexes with nucleosides and nucleoside analogues are also of current interest as model compounds; moreover, platinum(II) complexes with nucleotide derivatives of formula [PtCI(NH3)2(Am)] + (Am pyrimidine or purine derivative) have recently demonstrated activity in prclinical tumour screens, thus suggesting that also monofunctional DNA lesions might determine a cytotoxic effect (8) .
In our search on the platinum-coordination properties of acyclovir we synthesized a compound derived from cisplatin. 
MATERIALS AND METHODS
Synthesis of the complexes. 9-(2-hydroxyethoxymethyl)guanine (acyclovir, L1), 9-(2-acethoxyethoxymethyl)guanine (monoacetylacyclovir, L2) and 9-(2-acetoxyethoxymethyl)-N(2)-acetylguanine (diacetylacyclovir, L 3) were prepared by the method of Matsumoto et al. (9 (12) . Antitumour activity was expressed as %(T/C), with T the mean survival time oftreated mice and C that ofuntreated controls. Primer extension footprinting assay. The sequence selectivity of DNA modification by platinum complexes was evaluated by the primer extension footprinting assay (13, 14) . PBR 322 double stranded DNA (1.5x10 -8 mol nucleotides) was reacted with platinum complexes (drug/nucleotide molar ratio 0.02) in a total volume of 10 
RESULTS AND DISCUSSION
The structure of acyclovir (L1) is strikingly similar to that of guanosine but the rigid dbofuranosyl ring has been substituted by the more flexible 2-hydroxyethoxymthyl acyclic chain C(I')H2OC(2')H2C(3')H2OH. Moreover two derivatives acetylated at the 2-hydroxyethoxy position (L2) and at both 2-hydroxyethoxy and 2-amino positions (L3) have also been used. The acetyl groups confer different solubility characteristics to the ligands and related complexes, but should not modify N (7) The platinum-acyclovir complex shows an in vitro growth inhibitory capability, expressed as 50% growth inhibitory concentration (ID50) markedly lower than that of cisplatin: ID50 108 and 2 laM, respectively. Nevertheless, the platinum-acyclovir complex has a selective in vivo antitumour activity and shows the same efficacy of cisplatin in increasing the life span of animals treated with equitoxic dosages of the two componds (%T/C 209 and 211, respectively). Moreover, compound 4 is active against a cisplatinresistant subline of the P388 leukaemia (%T/C 140). Similarly to cationic platinum triamine complexes synthesized by Hollis (8, 11) , the platinum-acyclovir complex is less potent than cisplatin on a mole-equivalent basis. This behaviour might be related either to pharmacokinetic reasons, being platinum-acyclovir a charged compound, or to a different mechanism of action, as suggested by the absence of cross-resistance with cisplatin. In order to address the mechanistic properties of the platinum-acyclovir complex with respect to its anticancer activity, the sequence specificity of DNA modification and the DNA interstrand cross-linking ability were investigated and compared to those of cisplatin and [Pt(dien)Cl] +, a well known antitumour-inactive platinum-triamine complex. DNA (1.5x10 " mol nucleotides) was reacted with platinum complexes (drug/nucleotide 0.02) for 1 h at 37 C. The On a mole-equivalent basis the platinum-acyclovir complex is less active than the parent drugs, but it shows the same activity of cisplatin when administered at equitoxic dosages to P388 leukaemia-bearing mice. Moreover the platinum-acyclovir complex is active against the cisplatin-resistant P388 subline and is characterized by DNA interaction properties different from those of cisplatin, thus suggesting that a different mechanism of action could be operative.
